Nuvalent (NUVL) Gains from Investment Securities (2021 - 2026)
Nuvalent (NUVL) reported Gains from Investment Securities of $7.8 million for Q1 2026, down 33.48% on a YoY basis from $11.8 million in Q1 2025, and up 786.78% quarter-over-quarter from -$1.1 million in Q4 2025.
Nuvalent (NUVL) Gains from Investment Securities (2021 - 2026) Analysis & Trends
Nuvalent has reported Gains from Investment Securities for 6 years, with the latest figure at $7.8 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 33.48% year-over-year to $7.8 million; the trailing twelve-month figure through Mar 2026 stood at $7.8 million (up 110.14% YoY), and the FY2025 full-year result was $7.7 million, down 3.29% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $7.8 million, up from -$1.1 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $11.8 million in Q1 2025, with the low at -$72.6 million in Q4 2024.
- Historically, Gains from Investment Securities has averaged -$2.5 million across 5 years, with a median of $1.9 million in 2022.
- The largest YoY upside for Gains from Investment Securities was 322.88% in 2023 against a maximum downside of 357.22% in 2023.
- Nuvalent's Gains from Investment Securities stood at $6.5 million in 2022, then sank by 357.22% to -$16.6 million in 2023, then sank by 337.35% to -$72.6 million in 2024, then surged by 98.43% to -$1.1 million in 2025, then soared by 786.78% to $7.8 million in 2026.
- The last three Gains from Investment Securities figures came in at $7.8 million (Q1 2026), -$1.1 million (Q4 2025), and $74418.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.85 Mn |
| Mar 31, 2026 | 7.85 Mn |
| Dec 31, 2025 | -1.14 Mn |
| Dec 31, 2025 | -1.14 Mn |
| Sep 30, 2025 | 74,418.00 |
| Sep 30, 2025 | 74,418.00 |
| Jun 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 11.80 Mn |
| Mar 31, 2025 | 11.80 Mn |
| Dec 31, 2024 | -72.60 Mn |
| Dec 31, 2024 | -72.60 Mn |
| Sep 30, 2024 | 150,914.00 |
| Sep 30, 2024 | 150,914.00 |
| Jun 30, 2024 | 8.56 Mn |
| Jun 30, 2024 | 8.56 Mn |
| Dec 31, 2023 | -16.60 Mn |
| Dec 31, 2023 | -16.60 Mn |
| Sep 30, 2023 | 8.50 Mn |
| Sep 30, 2023 | 8.50 Mn |